SCHEMBL15419974

SCHEMBL15419974

CCS(=O)(=O)NC1CCOCC1COc1ccc(-c2ccc(Cl)cn2)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMO Q99835 1/20 0.34
TRPV4 Q9HBA0 3/20 0.33
GRM2 Q14416 1/20 0.33
KCNH2 Q12809 2/20 0.33
GPR119 Q8TDV5 2/20 0.33
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
FFAR1 O14842 2/20 0.32
CYP2C8 P10632 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
DGAT1 O75907 1/20 0.31
SCN1A P35498 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN8A Q9UQD0 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HTT P42858 1/20 0.31
MDM2 Q00987 1/20 0.31
GRM4 Q14833 1/20 0.31
GRM5 P41594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15441494 1.00 SMO (0.34) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL15420466 0.92 SMO (0.40) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL15420745 0.92 SMO (0.40) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL12987399 0.92 SMO (0.40) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL15420495 0.91 GRM5 (0.37) SMOGRM2ALOX5APFEN1FFAR1
SCHEMBL12988224 0.91 GRM5 (0.37) SMOGRM2ALOX5APFEN1FFAR1
SCHEMBL12988572 0.91 GRM5 (0.37) SMOGRM2ALOX5APFEN1FFAR1
SCHEMBL15420540 0.90 FEN1 (0.33) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL15420494 0.90 FEN1 (0.33) SMOTRPV4GRM2KCNH2GPR119
SCHEMBL15420363 0.90 FEN1 (0.33) SMOTRPV4GRM2KCNH2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 SMO 244/4885TRPV4 2130/4885GRM2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.